Evidence map›Paper›PMID 30779470›Full record

Trial reportJournal of clinical laboratory analysis2019

Increased serum adiponectin predicts improved coronary flow and clinical outcomes in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention.

Siwen Liang, Hongwei Li, Xuhua Shen, Ruifeng Liu

Abstract readClinical Trial
In one paragraph

Trial report in Journal of clinical laboratory analysis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Siwen LiangDepartment of Cardiology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.ORCID https://orcid.org/0000-0002-4421-7485
Hongwei LiDepartment of Cardiology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Xuhua ShenDepartment of Cardiology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Ruifeng LiuDepartment of Cardiology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.

Funding

Basic-Clinical Cooperation Program from Capital Medical University 15JL34
6 · The paper itself

Abstract

backgroundPrevious studies suggested that adiponectin (APN) could ameliorate ischemia/reperfusion injury and endothelial dysfunction in patients with acute myocardial infarction. However, the relationship between serum APN level and coronary flow after primary percutaneous coronary intervention (PPCI) in patients with ST-segment elevation myocardial infarction (STEMI) is unclear.

methodsA total of 144 patients with STEMI treated by PPCI were enrolled and divided into two groups based on the mean serum APN level on admission. The data on coronary angiograms and laboratory examinations were collected and compared between groups. The incidence of major adverse cardiac events (MACE) was evaluated in all enrolled patients.

resultsThe prevalence of Thrombolysis In Myocardial Infarction (TIMI) flow grade <3 after PPCI and corrected TIMI frame count were lower in the high-APN group (P = 0.032 and P = 0.029, respectively). Logistic regression analysis demonstrated that APN was an independent negative predictor of poor coronary flow after PPCI (odds ratio = 0.72, 95% CI: 0.56-0.93, P = 0.011). Kaplan-Meier curves showed that a higher APN level correlated with a better MACE-free survival rate, and multivariate Cox hazard regression analysis indicated that high APN was a significant negative predictor of MACE (hazard ratio = 0.54, 95% CI: 0.29-1.00, P = 0.048).

conclusionElevated serum levels of APN on admission are associated with improved myocardial blood flow and clinical outcomes in STEMI patients treated with PPCI.

Indexed as

AdiponectinAgedBiomarkersCoronary CirculationFemaleHumansKaplan-Meier EstimateLogistic ModelsMaleMiddle AgedPercutaneous Coronary InterventionST Elevation Myocardial InfarctionTreatment OutcomeAdiponectinADIPOQ protein, humanBiomarkersacute myocardial infarctionadiponectinmajor adverse cardiac eventmyocardial blood flowprimary percutaneous coronary intervention

Identifiers

PMID30779470
PMCPMC6595347

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.